Sonablate to undergo prostate cancer trials in US:
This article was originally published in Clinica
US researchers are to begin a clinical trial of Misonix' high intensity ultrasound (HIFU) treatment for prostate cancer, under an investigational exemption device from the FDA. The company's Sonablate 500 system will be used to treat around 40 patients at two sites. The HIFU technology can destroy deep-seated tissue by rapidly elevating the temperature in a precise focal zone, without affecting the intervening tissue and without ionisation effects, claims the Farmingdale, New York company. The device is currently in phase III US trials for the treatment of benign prostatic hyperplasia.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.